

Index

a

adhesion one 12
 adhesion torque 11–13, 15, 105
 Adriamycin 105
 adsorption, modularizing strategies for 238–239
 agarose microspheres
 performed polymer system 83
 uniform microspheres for
 chromatographic media 268–296
 agarose particles 139–141
 alginate microspheres 80, 89–93, 141–142, 185
 alginate particles 141–142, 185
 α -L-Guluronate (G) 141
 amino and hydroxyl groups 163
 anionic emulsifier 3, 121
 anticancer drugs
 novel biomimetic delivery strategies 222–224
 physical and chemical particle properties
 flexibility 210–211
 morphology 207–210
 size 203
 surface charge 203–206
 targeting tumor tissues
 externally-activated targeting 217–222
 ligand/receptor-induced targeting 211–212

tumor microenvironment sensitive targeting 212–217
 antigen-presenting cells (APCs) 137, 231–232, 234, 237–241, 244–246, 248, 251–255
 ARCoV 237
 Arlcel 83 109–110, 112, 166, 168–169
 asialoglycoprotein (ASGP) receptors 211

b

batch-to-batch stability 232, 257, 324
 β -D-Mannuronate (M) 141
 benzoyl peroxide (BPO) 28, 30, 33, 35, 46, 48, 132, 149
 biochemical engineering
 cell culture carriers 312–315
 super-porous microspheres for vaccine separation
 preparation methods for 297–303
 significance of 297
 uniform microspheres and super-porous microspheres in 268
 uniform microspheres for chromatographic media
 agarose microspheres 270–276
 Konjac Glucomannan (KGM) 276–280
 particle size 268–270
 PGMA microspheres 290–292
 PHEMA microspheres 292–293
 PST microspheres 280–290

- biochemical engineering (*contd.*)
 - silica microspheres 293–296
 - bio-degradable poly (lactide)
 - microspheres 41–42
 - biomimetic chitosan microsphere with
 - cell membrane 157
 - biomolecules separation
 - excellent flow hydrodynamics 306–307
 - virus-like particles (VLPs) separation 308–312
 - bioseparation 30, 32, 43, 140, 158, 269, 273–274, 276, 280
 - bioseparation engineering 267
 - biotechnology 73, 77, 267–269, 297, 316
 - Bovine serum albumin (BSA)
 - fluorescein isothiocyanate (FITC-BSA) 83
 - macromolecule 106
- C**
- CaCl₂ miniemulsions 141, 185
 - calcium alginate microspheres 80, 142
 - cationic emulsifiers 3
 - cell culture engineering 267
 - cellulose microspheres 93–94
 - cGAS-STING activators 232
 - chitosan gel particles 138–139
 - chitosan microspheres 63, 77–83
 - encapsulating water-insoluble drugs 154–155
 - oral administration via O/W/O 153–154
 - chitosan solid particles 136–137
 - coarse droplets (premixed emulsion) 129
 - composite microspheres
 - cross-linking agent 124–125
 - stabilizer in outer aqueous phase 123–124
 - water-soluble inhibitor 123
 - composition of polymers 113–114, 126
 - computational fluid dynamics (CFD) 16–19
 - continuous phase flow on emulsion
 - uniformity 11–13
 - core-shell-shell morphology (CSP1P2P3) 55
 - cosurfactant on morphology of composite
 - microspheres 52–56
 - cross flow drag force 6
 - cross-flow membrane emulsification 1
 - computational fluid dynamics 16–19
 - force balance model 6–8
 - Lattice Boltzmann method (LBM) 20–21
 - mechanism of droplet formation 2–5
 - surface evolver tool 19–20
 - torques balance model 8–16
 - cross-flow membrane emulsification (CME)
 - droplet formation 2–5, 323
 - force balance model 6–8
 - Torque balance model 8–9
 - cross-flow membrane emulsification
 - equipment 324–326
- d**
- Darcy law 9
 - denaturation 175–178, 183, 193, 304
 - detachment one 12
 - diethylenetriamine (DEAE) 40
 - diphenylmethane-4,4'-bisallylnagiimide (BANI-M) 40, 41
 - direct membrane emulsification 1, 35, 61, 69, 70, 73, 105
 - direct membrane emulsification
 - technique (MET) 8, 107–109, 118, 122, 129, 184, 323
 - dispersed-phase on emulsion uniformity 14–15
 - dispersed phase parameters 9–10
 - droplet size distribution 12–17, 69, 105, 118
 - droplets spontaneous detachments 4
 - drug delivery system (DDS) 43, 73, 95, 112, 126, 129, 164, 167, 195, 202, 212, 224

- drug-loaded particles from O/W emulsion
132
polydopamine microcapsules 135–136
via adsorption 133
via encapsulation 133–135
- drug-loading amount 116–117, 126
- dynamic droplet volume 10
- dynamic lift force 6, 7
- e**
- EGDMA 32, 33, 40, 300
- egg-box junctions 141
- elongative end pinching (EEP)
mechanism 328
- emulsifiers or stabilizer on emulsion
uniformity 15–16
- emulsifier/stabilizer on morphology of
microspheres 52
- emulsion in emulsion 105
- emulsion uniformity
continuous phase flow 11–13
dispersed-phase 14–15
emulsifiers or stabilizer 15–16
transmembrane pressure 13–14
- enhanced immune responses 232,
240
- enhanced permeability and retention
effect (EPR effect) 201
- externally-activated targeting
magnetism-based tumor targeting
217–218
photosensitive tumor targeting
219–220
thermal-responsive targeting 220–221
ultrasonic-induced targeting 221–222
- f**
- fluorescein isothiocyanate (FITC-BSA)
83
- force balance model 6–9
- g**
- gel microparticles (MGels) 138, 234
- Global Cancer Statistics 2020 201
- glucomannan microspheres 94–95
- glutaraldehyde 78–80, 95, 97, 98,
182–184, 187–189, 234
- GRT-350 62–67
- h**
- Hagen–Poiseuille equation 9
- high through-put membrane
emulsification equipment 325
- HTCC chitosan microspheres for oral
administration via O/W/O
153–154
- hydrophilic microspheres from W/O
emulsion
agarose particles 139–141
alginate particles 141–142
chitosan particles 136–139
Konjac Glucomanna particles
143–144
stimuli-responsive PNIPAM particles
139
- hydrophilic polymer microspheres from
W/O emulsion
membrane emulsification
polyvinyl alcohol (PVA) 95
protein microspheres 98
membrane modification and
preparation
hydrophobic membrane 67–73
hydrophobic modification 62–67
preformed polymer system 77–95
preparation microparticles from
monomer system 73–77
- hydrophobicity 55, 57, 62, 64, 67, 164,
206–207, 245
- hydrophobic membrane, preparation of
67–73
- hydrophobic microspheres from O/W
emulsion
drug-loaded particles 132–136
morphology control of microspheres
crosslinker 45–46
inert diluents 46–51
polylactide based particles from O/W
emulsion 130–131
preparation from monomer system

- hydrophobic microspheres from O/W emulsion (*contd.*)
- PGMA microspheres 31–32
 - PMMA microspheres 34–37
 - PST-DMAEMA microspheres 29–31
 - PST-DVB microspheres 28–29
 - PST-HEMA microspheres 32–34
- preparation from performed polymer system
- bio-degradable poly(lactide) microspheres 41–42
 - microcapsules containing inorganic materials 43
 - pickering emulsion 43–44
 - polyimide prepolymer (PIP) microspheres 40–41
 - polyurethane urea microspheres 39–40
 - PST-PMMA microspheres 37–39
 - PST particles 132
- hydrophobic modification, membrane 62–67
- hydrophobic organosilane compounds 66
- hydrophobic polypropylene membranes 69
- 10-hydroxycamptothecin (HCPT) nanocrystallites 211
- hydroxyethyl methacrylate (HEMA) 32
- hypoxia-targeted drug delivery 215–217
- i**
- industrialization 331–333
- inert diluents 46
- on morphology of microspheres
 - cosurfactant 52–56
 - emulsifier or stabilizer 52
 - non-solvating diluent effects 47–49
 - solvating diluent effects 49–51
 - inner aqueous phase volume 114–115
 - insoluble antitumor drugs 207, 208, 215
 - interfacial tension 4, 22
 - internal gelation technology 92
- in vivo anti-cancer drug carrier functions 203
- k**
- Konjac glucomannan (KGM) particles 94, 143, 276
- KP-18C 62
- Kupffer cells 203
- l**
- Lattice Boltzmann method (LBM) 20–21
- linear momentum force 7
- lipid nanoparticles (LNP) 236
- lipiodol W/O/W double emulsion 105
- liquid crystal displays (LCDs) 40
- localized shear forces 21
- m**
- macrophage uptake data 207
- magnetic O-carboxymethyl-chitosan nanoparticles 157
- magnetism-based tumor targeting 217–218
- mannosylated zwitterionic-based cationic liposome (man-ZCL) 242
- matrix metalloproteinase (MMP) 215
- membrane emulsification technology (MET) 29, 77, 323
- cross-flow 2
 - premix 1, 21–22
 - principles of 1
- microcapsule from double emulsion
- drug/antigen-loaded microcapsules via W/O/W emulsions
 - encapsulating water-soluble antigen 144–145
 - encapsulating water-soluble drugs 145–147
 - hollow particles for encapsulating antigen/drug 147
 - microspheres via O/W/O emulsion 152
 - biomimetic chitosan microsphere with cell membrane 157
 - chitosan microspheres 155–156

- encapsulating water-insoluble drugs 154–155
 - HTCC chitosan microspheres for oral administration via O/W/O 153–154
 - microspheres with unique structure via W/O/W emulsion
 - PLA/PLGA microspheres with single-core structure 147–149
 - PLGA microspheres with non-spherical structures 151–152
 - PMMA/PLGA microspheres with gigaporous structures 149–150
 - microcapsules 73
 - containing inorganic materials 43
 - with controllable structure
 - solidification rate of the droplets 119–121
 - stabilizer type 121
 - volume fraction of the inner aqueous phase 121
 - for drug encapsulation
 - composition of polymers 113–114
 - drug-loading amount 116–117
 - inner aqueous phase volume 114–115
 - microcapsules size 117–119
 - NaCl concentration in outer aqueous phase 115–116
 - pH-value in outer aqueous phase 117
 - microspheres
 - in biochemical engineering 267–316
 - related research 164
 - Mitomycin C 105
- n**
- NaCl concentration in outer aqueous phase 115
 - natural and synthetic polymers 163
 - natural biodegradable polymers 163
 - natural polymer (polysaccharide) chitosan
 - bioactivity of drugs
 - chitosan/alginate complex microsphere 193–194
 - cross-linking process 189–192
 - self-solidification system 192–193
 - step-wise crosslinking method 189
 - encapsulation efficiency
 - avoid drug crosslinking and leakage 184–185
 - drug loading 187–188
 - step-wise crosslinking method to avoid shrinkage stage 183–184
 - two-step solidification method to avoid drug leakage 185–187
 - NH₂ unit in 182
 - structure of 182
 - N-((2-hydroxy-3-trimethylammonium) propyl) chitosan chloride (HTCC) 80, 205
 - nonionic stabilizer 3
 - nonionic surfactants 92
 - non-solvating diluent effects on microsphere morphology 47
- o**
- oil-soluble emulsifier 109–110, 168
 - one-dimensional (1D) nanotubes 209
- p**
- particulate vaccine platforms
 - inorganic particles 235
 - lipid nanoparticles (LNP) 236
 - liposome 236
 - polymeric particles 234
 - polysaccharide particles 234
 - pathogen-associated molecular pattern (PAMP) 232
 - PELA 167
 - bioactivity of drugs
 - amphiphilic block polymer 178–180
 - denaturation 175–178
 - preparation and solidification method 180–181
 - encapsulation efficiency
 - effect of additives 168–169
 - pH in the external phase 169–170
 - polymer effect 170–171

- PELA (*contd.*)
 post-loading mode instead of
 pre-loading mode 174–175
 solidification technique 171–173
- PGMA microspheres 31, 290–292
- phase separations 48
- photosensitive tumor targeting 219–220
- pH-value in outer aqueous phase 117
- pickering emulsion 43–44, 142, 245, 247, 248
- “plug and play” platform 232
- P(GMA-DVB) microsphere 32
- P(GMA-EGDMA) microsphere 32
- PMMA microspheres 34
- poly (DL-lactide-co-glycolide acid) (PLGA) 166, 207, 234
- poly (lactic acid) (PLA) 164, 207
 based biodegradable polymers 164
 based drug delivery system 164
 polymers 207
- polydopamine microcapsules 135
- PolyDVB 51
- polyethylene (PE) 69
- polyimide prepolymer (PIP) microspheres 40
- polylactide acid (PLA) 234
- polymeric particles 234
- poly(N-isopropylacrylamide) (PNIPAM) microspheres 73
- poly (styrene)–poly(methyl methacrylate) (PST-PMMA) composite microspheres 55
- polysaccharide particles 234
- polytetrafluoroethylene (PTFE) 67
- polyurethaneurea microspheres 39
- polyurethaneurea-Vinyl Polymer (PUU-VP) microspheres 39
- polyvinyl alcohol (PVA) 95
 concentration, outer aqueous phase 110
- post-loading mode 150
- preformed polymer system
 agarose microspheres 83–89
 alginate microspheres 89–93
 cellulose microspheres 93–94
 chitosan microspheres 77–83
 glucomannan microspheres 94–95
- premix emulsification 1
- premix membrane emulsification (PME)
 technology 1, 105, 129, 323, 326
 interfacial tension effects 22
 localized shear forces 21–22
 steric hindrance between droplets 22
 transmembrane flux 21
- prepare smaller polystyrene (PST) microspheres 280–290
- particles from O/W emulsion 132
- spheres 130–132
- primary emulsion 105
- protein and polypeptide drugs 163
- protein microspheres 98
- proton sponge effect 206
- PST-DMAEMA microspheres 29
- PST-DVB microspheres 28
- PST-HEMA microspheres 32
- r**
- rapid membrane emulsification technique 1, 323
- recombinant human growth hormone (rhGH) 163, 164
- reticuloendothelial system (RES) 155, 204
- Reynolds number 7, 10
- rotary membrane emulsification (RME)
 equipment 329–331
 technology 323
- s**
- sandwich superstructure 209, 210
- shear-induced droplet formation (SHE) 3
- shearing force 6
- Shirasu porous glass (SPG) membrane 3, 61, 66, 118
- silica microspheres 293–296
- sodium alginate 90–92, 141, 142
- sodium lauryl sulfate (SLS) 28, 39
- solidification technique 171–173

- solid/oil/water (S/O/W) emulsion method 180
 - solvating diluent effects on microsphere morphology 49–51
 - spontaneous transformation-based droplet formation (STB) 3
 - stabilizer in outer aqueous phase 123–124, 126
 - step-wise crosslinking method 183–184, 189, 194
 - stimuli-responsive PNIPAM particles 139
 - Stokes equation 6
 - super-porous microspheres, advantages 268
 - super-porous microspheres for vaccine separation
 - biomolecules separation 306–312
 - preparation methods for 297
 - agarose microspheres 300–301
 - membrane emulsification technology 301–303
 - P(ST-DVB) microspheres 299, 304
 - significance of 297
 - surface hydrophilization of
 - super-porous PGMA microspheres 305–306
 - surface evolver tool 19–20
 - synthetic polymer
 - PELA 167
 - PLA 164–166
 - PLGA 166–167
- t**
- tetra glycerol condensed ricinoleate (TGCR) 98
 - thermal-responsive targeting 220–221
 - toll-like receptor (TLR) agonists 232
 - Torque balance model 324
 - continuous phase parameters 10
 - dispersed phase parameters 9–10
 - droplets uniformity 11–16
 - operation parameters 10–11
 - transmembrane pressure 110
 - on emulsion uniformity 13–14
 - microcapsules size distribution 110–112
 - trimethylol propane trimethacrylate (TMPTMA) 40, 41
 - triphenyl phosphorus (TPP) 223
 - triptorelin-loaded long-acting release (LAR) system 164
 - tumor microenvironment (TME) 202
 - sensitive targeting
 - enzyme responsive drug delivery 215
 - hypoxia-targeted drug delivery 215–217
 - pH-sensitive drug delivery 213–215
- u**
- ultrasonic-induced targeting 221–222
 - uniform droplet formation model 323
 - uniform microspheres 268
 - for chromatographic media
 - agarose microspheres 270–276
 - Konjac Glucomannan (KGM) 276–280
 - particle size 268–270
 - PGMA microspheres 290–292
 - PHEMA microspheres 292–293
 - PST microspheres 280–290
 - silica microspheres 293–296
 - upconversion NPs (UCNPs) 219, 223
- v**
- vaccination 231
 - modularizing strategies for
 - adsorption 238–239
 - chemical conjugation 239–240
 - encapsulation 237–238
 - multi-scale delivery of
 - distribution 249–252
 - internalization 252–253
 - presentation 254–255
 - particulate vaccine platforms 233–237
 - physicochemical traits
 - charge 241–242
 - hydrophobicity 245
 - shapes 243–244

vaccination (*contd.*)
size 240
softness 246–248
“vaccine chassis,” 232–239
vaccine formulations 231–257
virus-like particles (VLPs) separation
308–312

W

water-soluble inhibitor 30, 123,
126
W/O/W double emulsion
direct membrane emulsification
106
homogenization 106

preparation of composite microspheres
121
drug encapsulation 113
preparation of uniform microcapsules
microcapsules with controllable
structure 119
oil-soluble emulsifier 109–110
PLA microcapsules 108
pore size 112–113
PVA concentration in the outer
aqueous phase 110
transmembrane pressure 110–112

Z

zero-dimensional (0D) particles 209

